Patients were subsequently counselled about the risks associated with the pregnancy, particularly in the context of systemic comorbidities such as pre-existing diabetes, as well as the potential impact of anti-VEGF injections on these risks. This evidence concerns the gene VEGFA and diabetes mellitus.